A Phase 3 interventional study of tafamidis in Transthyretin Familial Amyloid Polyneuropathy, sponsored by Pfizer. Completed at 2 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-09-09.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Tafamidis has been developed as an oral specific stabilizer of transthyretin tetramer.
188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.
This study's enrollment of 10 is below the median of 54 across 90 interventional studies indexed under Amyloid Neuropathies, Familial.
Browse Amyloid Neuropathies, Familial studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
tafamidis
Drug: tafamidis
tafamidis meglumine 20 mg QD
Also known as: tafamidis meglumine
Number of Participants With Transthyretin (TTR) Stabilization at Week 8 Compared With Baseline as Measured by a Validated Immunoturbidimetric Assay
TTR tetramer level for each plasma sample was assessed using a validated immunoturbidimetric assay before and after urea denaturation. The Fraction of Initial (FOI) tetramer concentration is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer average concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI. A patient who has the "TTR stabilization" is defined as the patient whose percent stabilization is equal to or more than 32%.
Time frame: 8 weeks
Change From Baseline in Neuropathy Impairment Score (NIS); NIS (Total), NIS-LL (Lower Limb) and NIS-UL (Upper Limb) at Week 26, Week 52 and Week 78
The NIS provides a total body single score of neuropathic deficits (score range: 0-122, higher score = more deficit), comprising subset scores for cranial nerves, muscle weakness, reflexes, and sensation (based on mean of 2 scores in 1 week period; each item scored separately for left and right). The NIS-LL is a subscale that provides a score for the lower limbs functions (muscle weakness, reflexes and sensation in great toe) and has a score range of 0-44 (higher score = more deficit). The NIS-UL is a subscale that provides a score for the upper body functions (muscle weakness \[including cranial nerves\], reflexes and sensation in finger) and has a score range of 0-78 (higher score = more deficit). The components for cranial nerves and muscle weakness are scored from 0 (Normal) to 4 (Paralysis), and those for reflexes and sensation from 0 (Normal) to 2 (Absent). For all items, higher scores indicate greater impairment.
Time frame: Baseline, Week 26, Week 52, Week 78
Change From Baseline in Scores of the Total Quality of Life (TQOL) and 5 Domains as Measured by the Norfolk QOL - Diabetic Neuropathy (Norfolk QOL-DN) at Week 26, Week 52 and Week 78.
Norfolk QOL-DN is a 35-item participant-rated questionnaire. It consists of 5 domains: Physical Functioning/Large Fiber \[score range: -4 - 56\] , Activities of Daily Living (ADL) \[0 - 20\], Symptoms \[0 - 32\], Small Fiber \[0 - 16\] and Autonomic \[0 - 12\]. Total of quality of life (TQOL) score is the sum of all five domains with a range of -4 to 136 (Pfizer Data Standards). Higher scores on each item of the Norfolk QOL-DN TQOL indicate worse quality of life.
Time frame: Baseline, Week 26, Week 52, Week 78
Change From Baseline in Summated 7 Nerve Tests Normal Deviate Score (∑ 7 NTs Nds) as Measured by Nerve Conduction Studies (NCS), Vibration Detection Threshold (VDT) and Heart Rate Response to Deep Breathing (HRDB) at Week 26, Week 52, and Week 78
The Σ7 NTs nds measures primarily large-fiber function. It is a composite score derived from five NCS attributes (peroneal nerve distal motor latency, peroneal nerve compound muscle action potential, peroneal nerve motor conduction velocity, tibial nerve distal motor latency, and sural nerve sensory nerve action potential amplitude) along with VDT obtained in great toes by Quantitative Sensory Testing (QST), and HRDB value. It is defined as 7 times the mean of non-missing values of, the five normal deviates of NCS, HRDB, and average normal deviate for VDT of toes. Score was determined through reference to normal values for age, sex, height and abnormalities scored. Total score range is approximately -26 to 26, where higher score=worse nerve function.
Time frame: Baseline, Week 26, Week 52, Week 78
Change From Baseline in Summated 3 Nerve Tests Small Fiber Normal Deviate Score (∑ 3 NTSF Nds) as Measured by Cooling and Heat Pain Thresholds by QST and HRDB at Week 26, Week 52 and Week 78
The Σ3 NTSF nds measures small-fiber function. It is a composite score defined as 3 times the mean of non-missing values of normal deviates of cooling threshold for lower limbs, heat pain intermediate response for lower limbs, and HRDB. The total score range is approximately -11.2 to 11.2, with a higher score demonstrating worse nerve function.
Time frame: Baseline, Week 26, Week 52, Week 78
Change From Baseline in Modified Body Mass Index (mBMI) at Week 8, Week 26, Week 52 and End of Study
The mBMI was calculated by multiplying the BMI (the weight in kilograms divided by the square of the height in meters) by serum albumin level (gram/liter). Change in mBMI was calculated as the mBMI at the given week minus the Baseline mBMI.
Time frame: Baseline, Week 8, Week 26, Week 52, End of Study
Change From Baseline in Ambulatory Status at Week 26, Week 52 and Week 78
Ambulatory status was evaluated using walking ability scale in polyneuropathy disability score. The ambulatory status was evaluated as: 0=Good, 1=Sensory disturbances in the feet but able to walk without difficulty, 2=Some difficulties with walking but can walk without aid, 3a=Able to walk with 1 stick or crutch, 3b=Able to walk with 2 sticks or crutches, 4=Not ambulatory, confined to a wheelchair or bedridden.
Time frame: Baseline, Week 26, Week 52, Week 78
Number of Participants With Transthyretin (TTR) Stabilization at Week 26, Week 52, and Week 78 Compared With Baseline as Measured by a Validated Immunoturbidimetric Assay
TTR tetramer was assessed using a validated immunoturbidimetric assay. The TTR tetramer level for each plasma sample was measured before and after urea denaturation. The Fraction of Initial (FOI) tetramer concentration is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI. A patient who has the "TTR stabilization" is defined as the patient whose percent stabilization is equal to or more than 32%.
Time frame: Baseline, Week 26, Week 52, Week 78
Plasma Concentration of Tafamidis at Week 8, Week 26, Week 52 and Week 78
Mean plasma concentration of tafamidis at 3 hours after administration
Time frame: Week 8, Week 26, Week 52, Week 78
| Milestone | Tafamidis 20 mg |
|---|---|
| Started | 10 |
| Completed | 7 |
| Not completed | 3 |
| Withdrew: Death | 2 |
| Withdrew: Other | 1 |
TTR tetramer level for each plasma sample was assessed using a validated immunoturbidimetric assay before and after urea denaturation. The Fraction of Initial (FOI) tetramer concentration is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer average concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI. A patient who has the "TTR stabilization" is defined as the patient whose percent stabilization is equal to or more than 32%.
| Participants | Tafamidis 20 mg |
|---|---|
| Number of Participants With Transthyretin (TTR) Stabilization at Week 8 Compared With Baseline as Measured by a Validated Immunoturbidimetric Assay | 10 |
The NIS provides a total body single score of neuropathic deficits (score range: 0-122, higher score = more deficit), comprising subset scores for cranial nerves, muscle weakness, reflexes, and sensation (based on mean of 2 scores in 1 week period; each item scored separately for left and right). The NIS-LL is a subscale that provides a score for the lower limbs functions (muscle weakness, reflexes and sensation in great toe) and has a score range of 0-44 (higher score = more deficit). The NIS-UL is a subscale that provides a score for the upper body functions (muscle weakness \[including cranial nerves\], reflexes and sensation in finger) and has a score range of 0-78 (higher score = more deficit). The components for cranial nerves and muscle weakness are scored from 0 (Normal) to 4 (Paralysis), and those for reflexes and sensation from 0 (Normal) to 2 (Absent). For all items, higher scores indicate greater impairment.
| Units on a scale | Tafamidis 20 mg |
|---|---|
| NIS-Total: Baseline (n=10) | 31.03 ± 26.260 |
| NIS-Total: Change at Week 26 (n=10) | 4.37 ± 9.408 |
| NIS-Total: Change at Week 52 (n=10) | 8.30 ± 8.326 |
| NIS-Total: Change at Week 78 (n=8) | 9.90 ± 12.584 |
| NIS-LL: Baseline (n=10) | 16.99 ± 13.143 |
| NIS-LL: Change at Week 26 (n=10) | 2.06 ± 5.565 |
| NIS-LL: Change at Week 52 (n=10) | 3.62 ± 4.374 |
| NIS-LL: Change at Week 78 (n=8) | 3.30 ± 4.739 |
| NIS-UL: Baseline (n=10) | 14.03 ± 13.716 |
| NIS-UL: Change at Week 26 (n=10) | 2.31 ± 4.066 |
| NIS-UL: Change at Week 52 (n=10) | 4.68 ± 5.103 |
| NIS-UL: Change at Week 78 (n=8) | 6.59 ± 8.724 |
Norfolk QOL-DN is a 35-item participant-rated questionnaire. It consists of 5 domains: Physical Functioning/Large Fiber \[score range: -4 - 56\] , Activities of Daily Living (ADL) \[0 - 20\], Symptoms \[0 - 32\], Small Fiber \[0 - 16\] and Autonomic \[0 - 12\]. Total of quality of life (TQOL) score is the sum of all five domains with a range of -4 to 136 (Pfizer Data Standards). Higher scores on each item of the Norfolk QOL-DN TQOL indicate worse quality of life.
| Units on a scale | Tafamidis 20 mg |
|---|---|
| TQOL: Baseline (n=10) | 52.9 ± 32.76 |
| TQOL: Change at Week 26 (n=10) | 11.8 ± 20.01 |
| TQOL: Change at Week 52 (n=10) | 9.1 ± 12.49 |
| TQOL: Change at Week 78 (n=8) | 10.8 ± 13.69 |
| Physical Functioning: Baseline (n=10) | 25.6 ± 15.28 |
| Physical Functioning: Change at Week 26 (n=10) | 4.8 ± 10.02 |
| Physical Functioning: Change at Week 52 (n=10) | 2.2 ± 8.87 |
| Physical Functioning: Change at Week 78 (n=8) | 4.1 ± 7.83 |
| ADL: Baseline (n=10) | 8.5 ± 7.63 |
| ADL: Change at Week 26 (n=10) | 1.2 ± 3.61 |
| ADL: Change at Week 52 (n=10) | 0.8 ± 3.52 |
| ADL: Change at Week 78 (n=8) | 0.6 ± 2.33 |
| Symptoms: Baseline (n=10) | 8.5 ± 5.34 |
| Symptoms: Change at Week 26 (n=10) | 2.6 ± 3.47 |
| Symptoms: Change at Week 52 (n=10) | 4.0 ± 5.73 |
| Symptoms: Change at Week 78 (n=8) | 3.1 ± 3.94 |
| Small Fiber: Baseline (n=10) | 6.3 ± 5.31 |
| Small Fiber: Change at Week 26 (n=10) | 1.9 ± 4.25 |
| Small Fiber: Change at Week 52 (n=10) | 1.6 ± 2.32 |
| Small Fiber: Change at Week 78 (n=8) | 2.1 ± 3.76 |
| Autonomic: Baseline (n=10) | 4.0 ± 3.06 |
| Autonomic: Change at Week 26 (n=10) | 1.3 ± 1.42 |
| Autonomic: Change at Week 52 (n=10) | 0.5 ± 1.43 |
| Autonomic: Change at Week 78 (n=8) | 0.8 ± 1.91 |
The Σ7 NTs nds measures primarily large-fiber function. It is a composite score derived from five NCS attributes (peroneal nerve distal motor latency, peroneal nerve compound muscle action potential, peroneal nerve motor conduction velocity, tibial nerve distal motor latency, and sural nerve sensory nerve action potential amplitude) along with VDT obtained in great toes by Quantitative Sensory Testing (QST), and HRDB value. It is defined as 7 times the mean of non-missing values of, the five normal deviates of NCS, HRDB, and average normal deviate for VDT of toes. Score was determined through reference to normal values for age, sex, height and abnormalities scored. Total score range is approximately -26 to 26, where higher score=worse nerve function.
| Units on a scale | Tafamidis 20 mg |
|---|---|
| Baseline (n=10) | 8.33 ± 5.574 |
| Change at Week 26 (n=10) | 0.55 ± 2.657 |
| Change at Week 52 (n-=10) | 1.04 ± 2.992 |
| Change at Week 78 (n=8) | 1.92 ± 5.129 |
The Σ3 NTSF nds measures small-fiber function. It is a composite score defined as 3 times the mean of non-missing values of normal deviates of cooling threshold for lower limbs, heat pain intermediate response for lower limbs, and HRDB. The total score range is approximately -11.2 to 11.2, with a higher score demonstrating worse nerve function.
| Units on a scale | Tafamidis 20 mg |
|---|---|
| Baseline (n=10) | 6.39 ± 3.160 |
| Change at Week 26 (n=10) | 0.16 ± 1.619 |
| Change at Week 52 (n=10) | -0.13 ± 1.334 |
| Change at Week 78 (n=8) | 0.40 ± 1.985 |
The mBMI was calculated by multiplying the BMI (the weight in kilograms divided by the square of the height in meters) by serum albumin level (gram/liter). Change in mBMI was calculated as the mBMI at the given week minus the Baseline mBMI.
| (kilogram/square meter)*(gram/liter) | Tafamidis 20 mg |
|---|---|
| Baseline (n=10) | 805.70 ± 193.378 |
| Change at Week 8 (n=10) | 74.86 ± 88.706 |
| Change at Week 26 (n=10) | 26.61 ± 61.862 |
| Change at Week 52 (n=10) | 64.86 ± 80.016 |
| End of Study (n=7) | 53.65 ± 81.386 |
Ambulatory status was evaluated using walking ability scale in polyneuropathy disability score. The ambulatory status was evaluated as: 0=Good, 1=Sensory disturbances in the feet but able to walk without difficulty, 2=Some difficulties with walking but can walk without aid, 3a=Able to walk with 1 stick or crutch, 3b=Able to walk with 2 sticks or crutches, 4=Not ambulatory, confined to a wheelchair or bedridden.
| Participants | Tafamidis 20 mg |
|---|---|
| Baseline (n=10): Status 0 | 0 |
| Baseline (n=10): Status 1 | 3 |
| Baseline (n=10): Status 2 | 4 |
| Baseline (n=10): Status 3a | 2 |
| Baseline (n=10): Status 3b | 1 |
| Baseline (n=10): Status 4 | 0 |
| Week 26 (n=10): Status 0 | 1 |
| Week 26 (n=10): Status 1 | 2 |
| Week 26 (n=10): Status 2 | 3 |
| Week 26 (n=10): Status 3a | 2 |
| Week 26 (n=10): Status 3b | 2 |
| Week 26 (n=10): Status 4 | 0 |
| Week 52 (n=10): Status 0 | 1 |
| Week 52 (n=10): Status 1 | 1 |
| Week 52 (n=10): Status 2 | 4 |
| Week 52 (n=10): Status 3a | 2 |
| Week 52 (n=10): Status 3b | 2 |
| Week 52 (n=10): Status 4 | 0 |
| Week 78 (n=8): Status 0 | 1 |
| Week 78 (n=8): Status 1 | 1 |
| Week 78 (n=8): Status 2 | 2 |
| Week 78 (n=8): Status 3a | 2 |
| Week 78 (n=8): Status 3b | 2 |
| Week 78 (n=8): Status 4 | 0 |
TTR tetramer was assessed using a validated immunoturbidimetric assay. The TTR tetramer level for each plasma sample was measured before and after urea denaturation. The Fraction of Initial (FOI) tetramer concentration is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI. A patient who has the "TTR stabilization" is defined as the patient whose percent stabilization is equal to or more than 32%.
| Participants | Tafamidis 20 mg |
|---|---|
| Week 26 | 10 |
| Week 52 | 9 |
| Week 78 | 8 |
Mean plasma concentration of tafamidis at 3 hours after administration
| ng/mL | Tafamidis 20 mg |
|---|---|
| Week 8 (n=10) | 2773.0 ± 1777.71 |
| Week 26 (n=10) | 2739.0 ± 1893.25 |
| Week 52 (n=10) | 2829.0 ± 2315.58 |
| Week 78 (n=8) | 3655.0 ± 2268.08 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tafamidis 20 mg | — | 7/10 (70%) | 10/10 (100%) |
| Event | Tafamidis 20 mg |
|---|---|
| Pneumonia bacterialInfections and infestations | 3/10 |
| Atrioventricular block second degreeCardiac disorders | 1/10 |
| Sick sinus syndromeCardiac disorders | 1/10 |
| IleusGastrointestinal disorders | 1/10 |
| Sudden deathGeneral disorders | 1/10 |
| PyelonephritisInfections and infestations | 1/10 |
| Burns third degreeInjury, poisoning and procedural complications | 1/10 |
| Decreased appetiteMetabolism and nutrition disorders | 1/10 |
| Completed suicidePsychiatric disorders | 1/10 |
| Event | Tafamidis 20 mg |
|---|---|
| NasopharyngitisInfections and infestations | 5/10 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 5/10 |
| Thermal burnInjury, poisoning and procedural complications | 3/10 |
| CataractEye disorders | 2/10 |
| Vitreous opacitiesEye disorders | 2/10 |
| NauseaGastrointestinal disorders | 2/10 |
| VomitingGastrointestinal disorders | 2/10 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 2/10 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/10 |
| InsomniaPsychiatric disorders | 2/10 |
| Age, Continuous(years) | Tafamidis 20 mg |
|---|---|
| Mean | 60.1 ± 13.0 |
| Sex: Female, Male(Participants) | Tafamidis 20 mg |
|---|---|
| Female | 3 |
| Male | 7 |
The record gives a start of Nov 2011, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tafamidis
Amyloid Neuropathies, Familial →